Veradermics, Inc.
Clinical trials sponsored by Veradermics, Inc., explained in plain language.
-
New hair loss pill shows promise in early trial
Disease control OngoingThis Phase 2 study tests an investigational oral drug called VDPHL01 in 70 adults with mild to moderate pattern baldness. Participants take a tablet once or twice daily for 12 months. Researchers will measure changes in hair count and ask participants about perceived benefit. The…
Phase: PHASE2 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 25, 2026 07:38 UTC
-
Baldness breakthrough? new pill VDPHL01 heads to final testing
Disease control OngoingThis study tests a new daily pill, VDPHL01, for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 13 months. The main goal is to see if the drug increases hair count and if partici…
Phase: PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New pill could help men regrow hair
Disease control OngoingThis study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months…
Phase: PHASE2, PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC